OUR INVESTMENT CASE

We are a leading international provider of integrated state-of-the-art laboratory services to Blue Chip Pharma, NHS and Private Hospitals.

Our core business units deliver a solid EBITDA and cash generation. We have a strong balance sheet and are focussed on growing the business, both organically and inorganically. We completed the acquisition of LDPath in March 2022 and continue to seek further attractive M&A opportunities.

Read more at Source BioScience

AT A GLANCE

RNS
Announcements

Reports & Presentations

Board of
Directors

Shareholder
Information

RNS Announcements

Stay up to date with the latest RNS Announcements from SourceBio

Subscribe to alerts
SBI.L
SOURCEBIO INTERNATIONAL PLC ORD
LSE
125.00 GBp
0
0%

SourceBio – 2020 Investor Video

Watch Now

Source BioScience is an international provider of integrated state of the art Laboratory Services and Products. Headquartered in the UK, with sites in Cambridge, Rochdale, Ireland and San Diego, USA.

Source BioScience are leaders in conventional and next generation sequencing, gene expression and genotyping services as well as histopathology services, screening and reference laboratory diagnostic testing for cancer and other diseases. Our GMP compliant laboratories support an extensive range of equipment for analytical and physical chemistry and microbiology.

Continue reading…

A word from our Executive Chairman

SourceBio has built a strong balance sheet with substantial cash resources. It is now well positioned to accelerate growth in its three core business units, Healthcare Diagnostics, Genomics and Stability Storage – both organic and inorganic. It’s an exciting time for our business and we look forward to executing on our ambitious growth plans and delivering value to our shareholders.”

Jay LeCoque

Executive Chairman, SourceBio International